Vermillion Revenue 2006-2018 | VRML

Vermillion revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Vermillion Annual Revenue
(Millions of US $)
2017 $3
2016 $3
2015 $2
2014 $3
2013 $3
2012 $2
2011 $2
2010 $1
2009 $0
2008 $0
2007 $0
2006 $18
2005 $27
Vermillion Quarterly Revenue
(Millions of US $)
Q3 2018 $1
Q2 2018 $1
Q1 2018 $1
Q4 2017 $1
Q3 2017 $1
Q2 2017 $1
Q1 2017 $1
Q4 2016 $1
Q3 2016 $1
Q2 2016 $1
Q1 2016 $1
Q4 2015 $0
Q3 2015 $0
Q2 2015 $1
Q1 2015 $1
Q4 2014 $2
Q3 2014 $0
Q2 2014 $0
Q1 2014 $0
Q4 2013 $2
Q3 2013 $0
Q2 2013 $0
Q1 2013 $0
Q4 2012 $1
Q3 2012 $0
Q2 2012 $0
Q1 2012 $0
Q4 2011 $1
Q3 2011 $0
Q2 2011 $0
Q1 2011 $0
Q4 2010 $0
Q3 2010 $0
Q2 2010 $0
Q1 2010 $0
Q4 2009 $0
Q3 2009 $0
Q2 2009 $0
Q1 2009 $0
Q4 2008 $0
Q3 2008 $0
Q2 2008 $0
Q1 2008 $0
Q4 2007 $0
Q3 2007 $0
Q2 2007 $0
Q1 2007 $0
Q4 2006 $1
Q3 2006 $5
Q2 2006 $5
Q1 2006 $7
Q4 2005 $6
Q3 2005 $7
Q2 2005 $7
Q1 2005 $7
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $0.096B $0.003B
Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women's health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fremont, California.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $104.974B 23.66
Intuitive Surgical (ISRG) United States $64.396B 60.15
Edwards Lifesciences (EW) United States $37.346B 38.24
Fresenius Medical Care AG KGaA (FMS) Germany $24.137B 16.52
IDEXX Laboratories (IDXX) United States $18.595B 50.63
ABIOMED (ABMD) United States $15.024B 99.18
Teleflex (TFX) United States $13.940B 30.57
Hologic (HOLX) United States $13.875B 20.98
DexCom (DXCM) United States $13.590B 520.69
Varian Medical Systems (VAR) United States $12.400B 30.98
STERIS (STE) United Kingdom $10.436B 26.82
Masimo (MASI) United States $7.100B 44.21
Penumbra (PEN) United States $5.383B 304.57
Integra LifeSciences Holdings (IART) United States $4.774B 23.15
LivaNova (LIVN) United Kingdom $4.666B 28.52
Globus Medical (GMED) United States $4.605B 27.95
Tandem Diabetes Care (TNDM) United States $4.222B 0.00
Wright Medical Group (WMGI) Netherlands $4.069B 0.00
Cantel Medical (CMD) United States $2.836B 28.20
Integer Holdings (ITGR) United States $2.786B 22.73
Glaukos (GKOS) United States $2.612B 0.00
Inogen (INGN) United States $2.075B 41.36
AVANOS MEDICAL, INC (AVNS) United States $2.041B 22.17
OPKO Health (OPK) United States $1.545B 0.00
Nevro (NVRO) United States $1.327B 0.00
Tactile Systems Technology (TCMD) United States $1.189B 225.68
CryoLife (CRY) United States $1.120B 121.04
Pacific Biosciences Of California (PACB) United States $1.111B 0.00
Accelerate Diagnostics (AXDX) United States $1.079B 0.00
ORTHOFIX MEDICAL INC (OFIX) United States $1.077B 29.28
Luminex (LMNX) United States $1.071B 48.94
Intersect ENT (XENT) United States $1.047B 0.00
Natus Medical (BABY) United States $0.928B 19.34
Mesa Laboratories (MLAB) United States $0.913B 37.33
Veracyte (VCYT) United States $0.890B 0.00
AxoGen (AXGN) United States $0.812B 0.00
AngioDynamics (ANGO) United States $0.808B 26.20
ViewRay (VRAY) United States $0.782B 0.00
OrthoPediatrics (KIDS) United States $0.637B 0.00
Quotient (QTNT) Switzerland $0.622B 0.00
Fluidigm (FLDM) United States $0.537B 0.00
Oxford Immunotec Global (OXFD) United Kingdom $0.480B 50.56
Si-Bone (SIBN) United States $0.452B 0.00
GenMark Diagnostics (GNMK) United States $0.397B 0.00
Accuray (ARAY) United States $0.392B 0.00
Pulse Biosciences (PLSE) United States $0.375B 0.00
RTI Surgical (RTIX) United States $0.374B 54.54
Neuronetics (STIM) United States $0.291B 0.00
IRadimed (IRMD) United States $0.289B 61.14
SeaSpine Holdings (SPNE) United States $0.279B 0.00
Sientra (SIEN) United States $0.258B 0.00
Nuvectra (NVTR) United States $0.221B 0.00
Helius Medical Technologies (HSDT) United States $0.167B 0.00
Ekso Bionics Holdings (EKSO) United States $0.159B 0.00
Sensus Healthcare (SRTS) United States $0.148B 0.00
Alphatec Holdings (ATEC) United States $0.126B 0.00
ConforMIS (CFMS) United States $0.121B 0.00
Biosig Technologies (BSGM) United States $0.120B 0.00
T2 Biosystems (TTOO) United States $0.119B 0.00
Second Sight Medical Products (EYES) United States $0.101B 0.00
SOLITON INC (SOLY) $0.095B 0.00
EDAP TMS (EDAP) France $0.085B 0.00
Apollo Endosurgery (APEN) United States $0.073B 0.00
Titan Medical (TMDI) Canada $0.072B 0.00
HTG Molecular Diagnostics (HTGM) United States $0.068B 0.00
Ra Medical Systems (RMED) United States $0.056B 0.00
OBALON THERPTCS (OBLN) United States $0.042B 0.00
Avinger (AVGR) United States $0.038B 0.00
Microbot Medical (MBOT) United States $0.037B 0.00
Restoration Robotics (HAIR) United States $0.037B 0.00
Viveve Medical (VIVE) United States $0.029B 0.00
PAVmed (PAVM) United States $0.029B 0.00
Lianluo Smart (LLIT) China $0.025B 0.00
DarioHealth (DRIO) Israel $0.024B 0.00
Atossa Genetics (ATOS) United States $0.020B 0.00
Bioanalytical Systems (BASI) United States $0.020B 63.33
Dynatronics (DYNT) United States $0.018B 0.00
Presbia (LENS) Ireland $0.018B 0.00
ReWalk Robotics (RWLK) Israel $0.018B 0.00
ENDRA Life Sciences (NDRA) United States $0.016B 0.00
Nanovibronix (NAOV) United States $0.015B 0.00
Neovasc (NVCN) Canada $0.013B 0.00
Allied Healthcare Products (AHPI) United States $0.007B 0.00
Cesca Therapeutics (KOOL) United States $0.007B 0.00
SINTX TECHNOLOGIES, INC (SINT) United States $0.005B 0.00
Sunshine Heart Inc (CHFS) United States $0.002B 0.00
Check-Cap (CHEK) Israel $0.000B 0.00